# US 2025/0367116 A1 · Nitric oxide transporter for preventing or treating pulmonary arterial hypertension and method for manufacturing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367116 A1
- Document ID: US20250367116A1
- Status: Published application
- Kind: A1
- Application number: 19/185,822
- Filed: 2025-04-22
- Published: 2025-12-04
- Earliest claimed: 2024-06-04
- Assignees: Industry-Academic Cooperation Foundation, Yonsei University
- Applicants: Industry-Academic Cooperation Foundation, Yonsei University
- Inventors: Jin Kee HONG; Se Yong JUNG; Yoo Gyeong OH
- Web page: https://patentgrep.com/patent/US20250367116A1

## CPC

- A61K 9/113: Multiple emulsions, e.g. oil-in-water-in-oil {(A61K9/0026 takes precedence)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An embodiment relates to a method of preparing an inhalable type nitric oxide transporter capable of treating pulmonary arterial hypertension using a nebulizer, and more particularly, to a method of preparing a new type of therapeutic agent capable of treating pulmonary arterial hypertension more effectively by allowing particles having a low density due to high porosity of the particles to reach lesions deep in the lungs through a nebulizer. The inhalable type nitric oxide transporter of the embodiment has been confirmed to have effects such as inducing vasodilation, enhancing nitric oxide delivery efficiency, and inhibiting phagocytosis, and can be utilized as a therapeutic agent for pulmonary arterial hypertension.

## Claims

### Claim 1

An inhalable type nitric oxide transporter comprising a biodegradable polymer shell including a nitric oxide donor therein.

### Claim 2 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the nitric oxide donor is selected from the group consisting of a branched polyethyleneimine (BPEI)/NONOates complex, a pentaethylenehexamine (PEHA)/NONOates complex, and a spermine NONOates complex.

### Claim 3 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the biodegradable polymer is selected from the group consisting of hyaluronic acid, gelatin, starch, chitin, cellulose, alginate, collagen, heparin, chitosan, polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polydioxanone (PDO), poly(trimethylene carbonate) (PTMC), and polyhydroxyalkanoate (PHA).

### Claim 4 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the molecular weight of the BPEI/NONOates complex is 0.1 to 3.0 kDa.

### Claim 5 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the size of the transporter is 10 to 50 μm.

### Claim 6 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the transporter has high porosity.

### Claim 7 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the transporter continuously releases nitric oxide.

### Claim 8 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the transporter is not removed by phagocytes.

### Claim 9 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the transporter has low cytotoxicity and excellent biocompatibility.

### Claim 10 (depends on 1)

The inhalable type nitric oxide transporter according to claim 1, wherein the transporter promotes cyclic guanosine monophosphate (cGMP) synthesis and increases anti-inflammatory cytokine expression.

### Claim 11

A method of preparing an inhalable type nitric oxide transporter, comprising:
(a) a step of dissolving a nitric oxide donor in an aqueous solution to prepare a first aqueous phase (W1);
(b) a step of dissolving a biodegradable polymer in an organic solvent to prepare an oil phase (O);
(c) a step of mixing and dispersing the first aqueous phase (W1) and the oil phase (O) to prepare a W1/O emulsion;
(d) a step of mixing and dispersing the W1/O emulsion in a second aqueous phase (W2) including a surfactant to prepare a W1/O/W2 emulsion;
(e) a step of stirring the W1/O/W2 emulsion to evaporate the organic solvent and then remove the surfactant and residual substances; and
(f) a step of obtaining a nitric oxide transporter by freeze-drying after the removing step.

### Claim 12 (depends on 11)

The method of preparing the inhalable type nitric oxide transporter according to claim 11, wherein the nitric oxide donor is selected from the group consisting of a branched polyethyleneimine (BPEI/NONOates complex, a pentaethylenehexamine (PEHA)/NONOates complex, and a spermine NONOates complex.

### Claim 13 (depends on 11)

The method of preparing the inhalable type nitric oxide transporter according to claim 11, wherein the biodegradable polymer is selected from the group consisting of hyaluronic acid, gelatin, starch, chitin, cellulose, alginate, collagen, heparin, chitosan, polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polydioxanone (PDO), poly(trimethylene carbonate) (PTMC), and polyhydroxyalkanoate (PHA).

### Claim 14 (depends on 11)

The method of preparing the inhalable type nitric oxide transporter according to claim 11, wherein the aqueous solution is one or more selected from deionized water, a sodium acetate aqueous solution, an ammonium acetate aqueous solution, a phosphate acetate aqueous solution, a sodium citrate aqueous solution, and a sodium hydroxide aqueous solution.

### Claim 15 (depends on 11)

The method of preparing the inhalable type nitric oxide transporter according to claim 11, wherein the organic solvent is one or more selected from the group consisting of dichloromethane, dimethyl sulfoxide, chloroform, acetone, ethyl acetate, and ethyl ether.

### Claim 16 (depends on 11)

The method of preparing the inhalable type nitric oxide transporter according to claim 11, wherein the surfactant is one or more selected from the group consisting of polyvinyl alcohol (PVA), Tween 80, Pluronic F127, sodium carboxymethyl cellulose (NaCMC), gelatin, polysorbate, and polyethylene sorbitan monolaurate.

### Claim 17 (depends on 11)

The method of preparing the inhalable type nitric oxide transporter according to claim 11, wherein, in Step (e), stirring is performed for two to eight hours.

### Claim 18 (depends on 1)

A pharmaceutical composition for preventing or treating pulmonary arterial hypertension, comprising the inhalable type nitric oxide transporter according to claim 1 as an active ingredient.

### Claim 19 (depends on 18)

The pharmaceutical composition for preventing or treating pulmonary arterial hypertension according to claim 18, wherein the transporter is contained in an amount of 0.0001% to 1% by weight based on the total weight of the composition.

### Claim 20 (depends on 18)

The pharmaceutical composition for preventing or treating pulmonary arterial hypertension according to claim 18, wherein the pharmaceutical composition is injected using a nebulizer.
